Worcester, Massachusetts 01655


Purpose:

Clopidogrel is a medication that is used to decrease the ability of platelets to form blood clots. The theory has been proposed that, in patients with coronary artery disease or stroke, increased platelet function after discontinuation of clopidogrel therapy is associated with an increased clotting risk. However, this theory has never been rigorously tested. The goal of this research is to determine whether discontinuation of clopidogrel results in increased platelet function.


Study summary:

In this study, we will address the question: does discontinuation of clopidogrel result in platelet hyperreactivity? We will perform a double-blind, placebo-controlled, crossover study in normal subjects, in whom platelet reactivity will be measured before clopidogrel or placebo, during clopidogrel or placebo, and at various time points after discontinuation of clopidogrel or placebo. The dose of clopidogrel will be the standard, FDA-approved dose: 75 mg daily. All subjects will be treated with aspirin 81 mg daily throughout the 57 days of study assessment in both the clopidogrel arm and the placebo arm, because the clinically relevant question is: in patients who remain on aspirin, does discontinuation of clopidogrel result in platelet hyperreactivity?


Criteria:

Inclusion Criteria: - Must be a normal healthy subject - Must be between 21-70 years old - Must be able to take aspirin and clopidogrel. - Must be able to have blood drawn 16 times over approximately 3 months. Exclusion Criteria: - Subject who is currently taking aspirin or another anti-platelet drug such as clopidogrel. Subject must be free of these medications for 10 days before enrolling in this study. - Subject who is currently taking a non-steroidal anti-inflammatory drug such as ibuprofen or naproxen. Subject must be free of these medications for 3 days before enrolling in this study. - Subject who is currently taking medications for depression or medications that lower blood pressure or lower blood sugar. - Subject who are pregnant or may become pregnant during the study or who is breast feeding. - Subject with a known allergy to aspirin or clopidogrel. - Cigarette smoking or use of other nicotine product. - Subject with a history of any of the following: coronary artery disease; stroke; bleeding disorder; ongoing bleeding; previous life-threatening hemorrhage; stomach ulcers; gastrointestinal bleeding within the past 1 month; major surgery within the past 1 month; minor surgery within the past 2 weeks; or platelet transfusion within the past 7 days. - Subject with a blood count, measured on the pre-study drug blood sample, that is not in the normal range. - Subject who is enrolled in another clinical trial of an investigational drug.


NCT ID:

NCT00619073


Primary Contact:

Principal Investigator
Alan D. Michelson, M.D.
University of Massachusetts Medical School

Marsha L Fox, MS, RN
Phone: 508-856-0059
Email: fox@platelets.org


Backup Contact:

N/A


Location Contact:

Worcester, Massachusetts 01655
United States

Marsha L. Fox, MS, RN
Phone: 508-856-0059
Email: fox@platelets.org

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: January 22, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.